Loading...
Date of Award
Spring 2025
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Jamie Shaffer
Abstract
Irritable Bowel Syndrome (IBS) is a prevalent, chronic gastrointestinal disorder affecting approximately 4% of the global population. Despite its widespread impact, effective diagnosis and treatment remain challenging due to symptom overlap with other gastrointestinal conditions and the absence of definitive biomarkers. Diagnosis primarily relies on the Rome IV Criteria, which emphasizes symptom frequency and characteristics, and categorizes IBS into three subtypes: IBS-D (diarrhea-predominant), IBS-C (constipation-predominant), and IBS-M (mixed type). The pathophysiology is multifactorial, involving gut-brain axis dysregulation, altered gastrointestinal motility, inflammation, and significant psychological components such as anxiety and stress.
Recent advances in IBS management highlight the importance of individualized, holistic approaches to treatment. Dietary modifications, particularly the low-FODMAP diet, have demonstrated efficacy, especially in IBS-D. Pharmacologic treatments are subtype-specific, targeting underlying mechanisms to relieve symptoms. Cognitive Behavioral Therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) show promise in managing psychological comorbidities. Complementary therapies, including peppermint oil, probiotics, and acupuncture, offer additional symptom relief. Emerging technologies, such as telemedicine and AI-driven care models, are enhancing patient monitoring and treatment personalization. This comprehensive approach underscores the need for continued education, interdisciplinary collaboration, and innovative research to optimize outcomes for IBS patients.
Recommended Citation
Biro, Beata, "CME: Irritable Bowel Syndrome (IBS) - Advances and Individualized, Holistic Treatment Approaches" (2025). Capstone Showcase. 40.
https://scholarworks.arcadia.edu/showcase/2025/pa/40
CME: Irritable Bowel Syndrome (IBS) - Advances and Individualized, Holistic Treatment Approaches
Irritable Bowel Syndrome (IBS) is a prevalent, chronic gastrointestinal disorder affecting approximately 4% of the global population. Despite its widespread impact, effective diagnosis and treatment remain challenging due to symptom overlap with other gastrointestinal conditions and the absence of definitive biomarkers. Diagnosis primarily relies on the Rome IV Criteria, which emphasizes symptom frequency and characteristics, and categorizes IBS into three subtypes: IBS-D (diarrhea-predominant), IBS-C (constipation-predominant), and IBS-M (mixed type). The pathophysiology is multifactorial, involving gut-brain axis dysregulation, altered gastrointestinal motility, inflammation, and significant psychological components such as anxiety and stress.
Recent advances in IBS management highlight the importance of individualized, holistic approaches to treatment. Dietary modifications, particularly the low-FODMAP diet, have demonstrated efficacy, especially in IBS-D. Pharmacologic treatments are subtype-specific, targeting underlying mechanisms to relieve symptoms. Cognitive Behavioral Therapy (CBT) and selective serotonin reuptake inhibitors (SSRIs) show promise in managing psychological comorbidities. Complementary therapies, including peppermint oil, probiotics, and acupuncture, offer additional symptom relief. Emerging technologies, such as telemedicine and AI-driven care models, are enhancing patient monitoring and treatment personalization. This comprehensive approach underscores the need for continued education, interdisciplinary collaboration, and innovative research to optimize outcomes for IBS patients.